Investor Relations

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Stock Market
NASDAQSNGX
Featured Presentation

Soligenix Corporate Presentation

 

October 3, 2023

Dr. Brian Poligone, Clinical Investigator for CTCL Phase 3 FLASH Study, Answers Questions About Patient Care and Treatment Options

Read the Transcript

Latest News
Dec 1, 2023
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery

HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a...

Nov 30, 2023
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

Nov 17, 2023
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

All Press Releases

IR Contacts

29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com

Subscribe For Alerts

If you would like to receive our Investor Relations updates, please sign up for email alerts. 

 

 

Sign Up